Skip to main content
Premium Trial:

Request an Annual Quote

NIAMS to Fund Research Cores for Musculoskeletal Conditions

NEW YORK (GenomeWeb News) – The National Institute of Arthritis and Musculoskeletal and Skin Diseases plans to use up to $2.4 million next year to fund the creation of several core centers that will support scientists studying the underlying biology of muscle and bones and the range of disorders that affect them.

The Core Centers for Musculoskeletal Biology and Medicine will offer shared resources and services to currently funded researchers with the aim of enhancing and speeding up their efforts and making them more cost-effective and efficient.

NIAMS plans to fund three or four awards with up to $400,000 each in Fiscal Year 2014. The funding will support two or more research cores, an administrative core, and an enrichment program at each of the institutions receiving funding.

These core centers will provide technologies for applications such as high-throughput sequencing, genotyping, and histology that lend themselves to standardized procedures; complex instrumentation for microarray scanning, mass spectrometry, confocal microscopy, and whole animal imaging, among others; methodology cores for projects involving systems biology, bioinformatics, molecular biology, biostatistics, and cell biology; and resources for animal preparation, including transgenic and knockout services.

The resources at these cores may include personnel, equipment, supplies, services, and facilities.

NIAMS-funded researchers conduct studies aimed at improving the diagnosis, treatment, and prevention of diseases and injuries of the musculoskeletal system and its tissues, including osteoporosis, osteoarthritis, and muscular dystrophy.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more